CSPC PHARMA(01093): Potent aldosterone synthase inhibitor (SYH2072 tablets) granted clinical trial approval in the United States.

CSPC PHARMA (01093) announced that the Group's newly developed Category 1 drug, a potent aldosterone synthase inhibitor (SYH2072 tablets), has been approved by the U.S. Food and Drug Administration for clinical trials in the United States. The product has also been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China in December 2025. This product is a highly selective potent aldosterone synthase inhibitor (ASI) that can effectively reduce plasma aldosterone levels without affecting cortisol levels. The approved clinical indications for this product are uncontrolled hypertension and refractory hypertension. Preclinical studies have shown that this product selectively inhibits the activity of aldosterone synthase, significantly reduces plasma aldosterone levels in animal disease models, and dose-dependently lowers blood pressure in hypertension models, while not affecting cortisol levels. The product has good pharmacokinetic (PK) properties and safety, making it a potential best-in-class drug. Currently, the Group has submitted multiple patent applications for this product domestically and internationally. Given the broad clinical demand for aldosterone synthase inhibitors, this product has high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and refractory hypertension.